Drug Search Results
More Filters [+]

Lecozotan

Alternative Names: lecozotan, sra-333, sra333, sra 333
Latest Update: 2022-05-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT1A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lecozotan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Alzheimer Disease

Phase 1: Alzheimer Disease|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

3098B1-1142

P1

Completed

Alzheimer Disease

2008-09-01

2005-001478-28

P2

Completed

Alzheimer Disease

2008-06-11

3098B1-203, 3098B1-204

P3

Completed

Alzheimer Disease

2008-06-01

36%

3098B1-201, 3098B1-202

P2

Completed

Alzheimer Disease

2008-03-15

32%

Recent News Events

Date

Type

Title